Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-06-09T10:19:48.070Z Has data issue: false hasContentIssue false
  • English
  • Français

ENGAGING CLINICIANS IN EVIDENCE-BASED DISINVESTMENT: ROLE AND PERCEPTIONS OF EVIDENCE

Published online by Cambridge University Press:  14 September 2012

Amber M. Watt ,
Cameron D. Willis ,
Katherine Hodgetts ,
Adam G. Elshaug  and
Janet E. Hiller
Amber M. Watt
Affiliation:
The University of Adelaide
Cameron D. Willis
Affiliation:
The University of Adelaide
Katherine Hodgetts
Affiliation:
The University of Adelaide
Adam G. Elshaug
Affiliation:
The University of Adelaide; Harvard Medical School email: elshaug@hcp.med.harvard.edu
Janet E. Hiller
Affiliation:
Australian Catholic University
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to determine how evidence from systematic review (SR) is perceived and negotiated by expert stakeholders in considering a technology for potential disinvestment.

Methods: An evidence-informed stakeholder engagement examined results from a diagnostic accuracy SR of vitamin B12 and folate tests. Pathologists deliberated around the SR findings to generate an informed contribution to future policy for the funding of B12 and folate tests. Deliberations were transcribed and subject to qualitative analysis.

Results: Pathologists did not engage with findings from the SR in depth; rather they sought to contest the terms of the problem driving the review and attempted to reframe it. Pathologists questioned the usefulness of SR outcomes given the variable definitions of B12 deficiency and deferred addressing disinvestment options specifically pertaining to B12 testing. However, folate testing was proffered as a potential disinvestment candidate, based upon pathologists' definition of “appropriate” evidence beyond the bounds of the SR.

Conclusions: The value of SR to informing disinvestment deliberations by expert stakeholders may be a function of timing as well as content. Engagement of stakeholders in co-produced evidence may be required at two levels: (i) Early in the synthesis phase to help shape the SR and harmonize expert views with the available evidence (including gaps); (ii) Collaboration in primary research to fill evidence-gaps thus supporting evidence-based disinvestment. Without this, information asymmetry between clinically engaged experts and decision makers may preclude the collaborative, informed, and technical discussions required to generate productive policy change.

Keywords

DisinvestmentQualitative researchSystematic reviewEvidence-based practiceHealth policy
Type
MINITHEME: DISINVESTMENT
Information
International Journal of Technology Assessment in Health Care , Volume 28 , Issue 3 , July 2012 , pp. 211 - 219
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Australian Government Department of Health and Ageing. Proposal for changes to the Medical Services Advisory Committee (MSAC) processes for applications for public funding. Canberra: Australian Government Department of Health and Ageing; 2010.Google Scholar
2.Bayram, CH, Britt, H, Miller, G, Valenti, L. Evidence-practice gap in GP pathology test ordering: A comparison of BEACH pathology data and recommended testing. Sydney: The University of Sydney, School of Public Health; 2009.Google Scholar
3.bpac nz. Laboratory investigation of tiredness. Dunedin: bpac nz, 2006.Google Scholar
4.Braun, V, Clarke, V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.CrossRefGoogle Scholar
5.Edley, N. Analysing masculinity: Interpretatative repertoires, subject positions and ideological dilemmas . In: Wetherell, M, Taylor, S, Yates, SJ, eds. Discourse as data: A guide to analysis. London: Sage and the Open University; 2001:189–228.Google Scholar
6.Elshaug, AG, Hiller, JE, Moss, JR. Exploring policy-makers’ perspectives on disinvestment from ineffective healthcare practices. Int J Technol Assess Health Care. 2008;24:1–9.CrossRefGoogle ScholarPubMed
7.Elshaug, AG, Hiller, JE, Tunis, SR, Moss, JR. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust New Zealand Health Policy. 2007;4:23.CrossRefGoogle ScholarPubMed
8.Elshaug, AG, Moss, JR, Littlejohns, P, et al.Identifying existing health care services that do not provide value for money. Med J Aust. 2009;190:269–273.CrossRefGoogle Scholar
9.Gerdvilaite, J, Nachtnebel, A. Disinvestment: Overview of disinvestment experiences and challenges in selected countries. HTA-Projektbericht, Ludwig Boltzmann Institut für Health Technology Assessment; 2011.Google Scholar
10.Guidelines and Protocols Advisory Committee. B12 deficiency - investigation & management of vitamin B12 and folate deficiency. Vancouver, BC: Guidelines and Protocols Advisory Committee, 2006.Google Scholar
11.Lin, V, Gibson, B. Introduction. In: Lin, V, Gibson, B, eds. Evidence-based health policy. Problems and possibilities. Melbourne: Oxford University Press; 2003.Google Scholar
12.Lomas, J, Culyer, T, McCutcheon, C, McAuley, L, Law, S. Conceptualizing and combining evidence for health system guidance. Ottawa: Canadian Health Services Research Foundation; 2005.Google Scholar
13.Mays, N, Pope, C, Popay, J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10:16–20.CrossRefGoogle ScholarPubMed
14.Medical Benefits Reviews Task Group. Review of the funding arrangements for pathology services. Canberra: Department of Health and Ageing; 2011.Google Scholar
15.Medicare Australia. MBS items statistics reports. Canberra: Department of Health and Ageing; 2011.Google Scholar
16.Menon, D, Stafinski, T. Health Technology Assessment in Canada: 20 years strong? Value Health. 2000;12:14–19.CrossRefGoogle Scholar
17.Ontario Association of Medical Laboratories. Guidelines for folate testing (CLP-026). New York: Ontario Association of Medical Laboratories; 2009.Google Scholar
18.Pawson, R. Evidence-based policy: The promise of ‘realist synthesis’. Evaluation. 2002;8:340–358.CrossRefGoogle Scholar
19.Pearson, SD, Rawlins, MD. Quality, innovation, and value for money. NICE and the British National Health Service. JAMA. 2005;294:2618–2622.CrossRefGoogle ScholarPubMed
20.Royal College of Pathologists of Australasia. RCPA Manual. Sydney: Royal College of Pathologists of Australasia; 2009.Google Scholar
21.Sampietro-Colom, L, Ausa, J, Briones, E, Gol, J, AuNETS Group. History of health technology assessment: Spain. Int J Technol Assess Health Care. 2009;25:163–173.CrossRefGoogle ScholarPubMed
22.Willis, CD, Elshaug, AG, Milverton, JL, et al.Diagnostic performance of serum cobalamin tests: A systematic review and meta-analysis. Pathology. 2011;43:472–481.CrossRefGoogle ScholarPubMed